Statins and sepsis: multiple modifications at multiple levels

Marius Terblanche, Yaniv Almog, Robert S. Rosenson, Terry S. Smith, Daniel G. Hackam

    Research output: Contribution to journalReview articlepeer-review

    240 Scopus citations

    Abstract

    Sepsis, an infection-induced inflammatory syndrome, is a leading and increasing cause of mortality worldwide. Animal and human observational studies suggest statins may prevent the morbidity and mortality associated with the sepsis syndrome. In this Review, we describe the demonstrated mechanisms through which statins modulate the inflammatory response associated with sepsis. These mechanisms include effects on cell signalling with consequent changes at the transcriptional level, the induction of haem oxygenase, the direct alteration of leucocyte-endothelial cell interaction, and the reduced expression of MHC II. Since statins do not target individual inflammatory mediators, but possibly reduce the overall magnitude of the systemic response, this effect could prove an important distinguishing feature modulating the host response to septic insults. This work establishes the biological plausibility needed for future trials of statins in critical illness.

    Original languageEnglish
    Pages (from-to)358-368
    Number of pages11
    JournalThe Lancet Infectious Diseases
    Volume7
    Issue number5
    DOIs
    StatePublished - 1 May 2007

    ASJC Scopus subject areas

    • Infectious Diseases

    Fingerprint

    Dive into the research topics of 'Statins and sepsis: multiple modifications at multiple levels'. Together they form a unique fingerprint.

    Cite this